OpenArc Corporate Advisory’s Novo Nordisk NVO Stock Holding History

OpenArc Corporate Advisory’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$527K	Buy	10,991 +2,019	+23%	+$86.7K	0.01%	474
2026 Q1	$330K	Sell	8,972 -558	-6%	-$26.4K	﹤0.01%	545
2025 Q4	$485K	Buy	+9,530	New	+$487K	0.01%	407

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

OpenArc Corporate Advisory's NVO Position: Q2 2026 in Review

OpenArc Corporate Advisory increased its Novo Nordisk (NVO) stake by 23% in Q2 2026, buying an estimated $86.7K and bringing the position to 10,991 shares worth $527K. The position accounts for 0.01% of the portfolio, ranked #474.

OpenArc Corporate Advisory first reported a position in NVO in Q4 2025 and has held it in 3 quarters since. 1,356 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

OpenArc Corporate Advisory held 10,991 shares of Novo Nordisk worth $527K as of Q2 2026.
OpenArc Corporate Advisory bought 2,019 Novo Nordisk shares in Q2 2026, an estimated $86.7K.
Novo Nordisk made up 0.01% of OpenArc Corporate Advisory's portfolio in Q2 2026, its #474 holding.
OpenArc Corporate Advisory first reported a position in Novo Nordisk in Q4 2025 and has held it in 3 quarters since.
1,356 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on OpenArc Corporate Advisory's 13F filing for Q2 2026, filed 5 Aug 2026.